Role of diffusion-weighted MRI in assessing Ewing sarcoma treatment response: Findings from a COG phase III trial.
Ricarda von Krüchten, Natalie J DelRocco, Lisa C Adams et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase III multicenter trial evaluated the correlation between diffusion-weighted MRI measures and glucose metabolism in 21 patients with metastatic Ewing sarcoma. The study found that baseline ADC mean of viable tumors inversely correlated with SUV max (R = -0.51, p = 0.022), indicating potential for ADC mean as a surrogate for metabolic activity, though no imaging biomarkers were linked to event-free survival.
Key findings
- Baseline ADC mean of viable tumors inversely correlated with SUV max (R = -0.51, p = 0.022).
- Post-induction SUV max inversely correlated with whole tumor ADC min (R = -0.59, p = 0.028).
- Post-induction whole tumor ADC min correlated with tumor volume changes (R = -0.56, p = 0.008).
- No imaging biomarkers were associated with event-free survival risk.
Why it matters
Understanding the relationship between imaging biomarkers and tumor metabolism can enhance treatment monitoring in Ewing sarcoma. This study suggests that diffusion-weighted MRI may provide valuable insights into tumor response to therapy, although its implications for survival outcomes remain unclear.